Anderson Joseph C, Baron John A, Ahnen Dennis J, Barry Elizabeth L, Bostick Roberd M, Burke Carol A, Bresalier Robert S, Church Timothy R, Cole Bernard F, Cruz-Correa Marcia, Kim Adam S, Mott Leila A, Sandler Robert S, Robertson Douglas J
Department of Medicine, Department of Veterans Affairs Medical Center, White River Junction, Vermont; Department of Epidemiology for ELB, JAB, and LM and Department of Medicine in the Division of Gastroenterology and Hepatology for JCA and DJR, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Department of Epidemiology for ELB, JAB, and LM and Department of Medicine in the Division of Gastroenterology and Hepatology for JCA and DJR, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; Department of Medicine in the Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Gastroenterology. 2017 Jun;152(8):1933-1943.e5. doi: 10.1053/j.gastro.2017.02.010. Epub 2017 Feb 20.
BACKGROUND & AIMS: Endoscopists do not routinely follow guidelines to survey individuals with low-risk adenomas (LRAs; 1-2 small tubular adenomas, < 1 cm) every 5-10 years for colorectal cancer; many recommend shorter surveillance intervals for these individuals. We aimed to identify the reasons that endoscopists recommend shorter surveillance intervals for some individuals with LRAs and determine whether timing affects outcomes at follow-up examinations.
We collected data from 1560 individuals (45-75 years old) who participated in a prospective chemoprevention trial (of vitamin D and calcium) from 2004 through 2008. Participants in the trial had at least 1 adenoma, detected at their index colonoscopy, and were recommended to receive follow-up colonoscopy examinations at 3 or 5 years after adenoma identification, as recommended by the endoscopist. For this analysis we collected data from only participants with LRAs. These data included characteristics of participants and endoscopists and findings from index and follow-up colonoscopies. Primary endpoints were frequency of recommending shorter (3-year) vs longer (5-year) surveillance intervals, factors associated with these recommendations, and effect on outcome, determined at the follow-up colonoscopy.
A 3-year surveillance interval was recommended for 594 of the subjects (38.1%). Factors most significantly associated with recommendation of 3-year vs a 5-year surveillance interval included African American race (relative risk [RR] to white, 1.41; 95% confidence interval [CI], 1.14-1.75), Asian/Pacific Islander ethnicity (RR to white, 1.7; 95% CI, 1.22-2.43), detection of 2 adenomas at the index examination (RR vs 1 adenoma, 1.47; 95% CI, 1.27-1.71), more than 3 serrated polyps at the index examination (RR=2.16, 95% CI, 1.59-2.93), or index examination with fair or poor quality bowel preparation (RR vs excellent quality, 2.16; 95% CI, 1.66-2.83). Other factors that had a significant association with recommendation for a 3-year surveillance interval included family history of colorectal cancer and detection of 1-2 serrated polyps at the index examination. In comparisons of outcomes, we found no significant differences between the 3-year vs 5-year recommendation groups in proportions of subjects found to have 1 or more adenomas (38.8% vs 41.7% respectively; P = .27), advanced adenomas (7.7% vs 8.2%; P = .73) or clinically significant serrated polyps (10.0% vs 10.3%; P = .82) at the follow-up colonoscopy.
Possibly influenced by patients' family history, race, quality of bowel preparation, or number or size of polyps, endoscopists frequently recommend 3-year surveillance intervals instead of guideline-recommended intervals of 5 years or longer for individuals with LRAs. However, at the follow-up colonoscopy, similar proportions of participants have 1 or more adenomas, advanced adenomas, or serrated polyps. These findings support the current guideline recommendations of performing follow-up examinations of individuals with LRAs at least 5 years after the index colonoscopy.
内镜医师通常不遵循指南,每5 - 10年对低风险腺瘤(LRA;1 - 2个小的管状腺瘤,<1 cm)患者进行结直肠癌筛查;许多人建议对这些患者采用更短的监测间隔。我们旨在确定内镜医师建议对某些LRA患者采用更短监测间隔的原因,并确定时间安排是否会影响随访检查的结果。
我们收集了1560名年龄在45 - 75岁之间的个体的数据,这些个体参与了2004年至2008年的一项前瞻性化学预防试验(维生素D和钙)。该试验的参与者在初次结肠镜检查时至少发现1个腺瘤,并根据内镜医师的建议,在腺瘤确诊后3年或5年接受随访结肠镜检查。对于本分析,我们仅收集了LRA患者的数据。这些数据包括参与者和内镜医师的特征以及初次和随访结肠镜检查的结果。主要终点是建议较短(3年)与较长(5年)监测间隔的频率、与这些建议相关的因素以及在随访结肠镜检查时对结果的影响。
594名受试者(38.1%)被建议采用3年的监测间隔。与建议3年而非5年监测间隔最显著相关的因素包括非裔美国人种族(相对于白人的相对风险[RR]为1.41;95%置信区间[CI],1.14 - 1.75)、亚裔/太平洋岛民种族(相对于白人的RR为1.7;95% CI,1.22 - 2.43)、初次检查时发现2个腺瘤(相对于1个腺瘤的RR为1.47;95% CI,1.27 - 1.71)、初次检查时超过3个锯齿状息肉(RR = 2.16,95% CI,1.59 - 2.93)或初次检查时肠道准备质量为中等或较差(相对于高质量的RR为2.16;95% CI,1.66 - 2.83)。与建议3年监测间隔有显著关联的其他因素包括结直肠癌家族史以及初次检查时发现1 - 2个锯齿状息肉。在结果比较中,我们发现3年建议组与5年建议组在随访结肠镜检查时发现有1个或更多腺瘤的受试者比例(分别为38.8%和41.7%;P = 0.27)、高级别腺瘤比例(7.7%和8.2%;P = 0.73)或具有临床意义的锯齿状息肉比例(10.0%和10.3%;P = 0.82)方面没有显著差异。
内镜医师可能受患者家族史、种族、肠道准备质量或息肉数量或大小的影响,经常建议对LRA患者采用3年的监测间隔,而非指南推荐的5年或更长时间。然而,在随访结肠镜检查时,具有1个或更多腺瘤、高级别腺瘤或锯齿状息肉的参与者比例相似。这些发现支持了当前指南的建议,即对LRA患者在初次结肠镜检查后至少5年进行随访检查。